Pioneering GIP
receptor antagonism for obesity treatment

We’re addressing obesity and overweight through GIP receptor antagonism, developing treatments that go beyond weight loss to deliver long-term sustained health, without compromising on tolerability.

GIP receptor antagonism

Unlike therapies that stimulate incretin-driven suppression of appetite, GIP receptor antagonism is a novel therapeutic approach that not only holds the potential to deliver significant weight loss but also improve long-term health in patients.

Preclinical studies have demonstrated substantial weight loss with an excellent tolerability profile. Additionally, the combination with GLP-1s has shown additive effects with no added gastrointestinal burden as well as improvements in cardiovascular outcomes, healthier body composition, and lean mass preservation.

By antagonising the GIP receptor in people with overweight and obesity, our approach addresses a dysregulated biological pathway that otherwise contributes to excessive fat storage, insulin resistance, and metabolic dysfunction.